ANDA Challenges To Formulation Patents May Get Easier After KSR Ruling
The pharmaceutical industry could have a tougher time protecting certain drug patents - particularly those in ANDA litigation - following a U.S. Supreme Court decision that expands the situations under which an invention can be considered obvious
More from Archive
More from Pink Sheet
The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.
The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges